Search results for "infarct"

showing 10 items of 1223 documents

Troponin T — a reliable marker of perioperative myocardial infarction?

1993

Following cardiac surgery, electrocardiography and creatine kinase isoenzyme MB (CK-MB) activities are of limited value in diagnosing a non-transmural infarction. With the recent availability of an assay to detect serial levels of the specific cardiocyte contractile protein troponin T the possibility has been increased of closing a diagnostic gap among cardiosurgical patients. Ninety patients with severe diffuse three-vessel disease undergoing myocardial revascularization were grouped by their postoperative electrocardiographic (ECG) findings (group I--unchanged ECG; group II--new Q-waves representing perioperative myocardial infarction (PMI)). Serial levels of troponin T and the activity o…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyMicrogramMyocardial InfarctionInfarctionCoronary DiseaseSensitivity and SpecificityElectrocardiographyPostoperative ComplicationsTroponin TPredictive Value of TestsInternal medicinemedicineHumansMyocardial infarctionCreatine KinaseAgedBundle branch blockmedicine.diagnostic_testbiologyTroponin Tbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseTroponinTroponinIsoenzymesQuartileCardiologybiology.proteinFemaleSurgeryCardiology and Cardiovascular MedicinebusinessElectrocardiographyBiomarkersEuropean Journal of Cardio-Thoracic Surgery
researchProduct

Prognostic value of fragmented QRS on a 12-lead ECG in patients with acute myocardial infarction

2013

Abstract Objective To investigate the determinants and the prognostic value of fragmented QRS (fQRS) after AMI. Patients and methods Prospective cohort of 307 consecutive patients with AMI. Main outcomes measured MACE (death plus non-fatal recurrent MI), hospitalization for an episode of heart failure, ventricular arrhythmia (VT or VF) at two years follow-up. Results On the serial 12-lead ECG recorded during the in-hospital stay, 162 (53%) had no fQRS ( no fQRS group ). 145 (47%) presented an fQRS, which was persistent in 108 (34%) patients ( persistent fQRS group ) and transient in 37 (12%) patients ( transient fQRS group ). Patients with a fragmented QRS (transient or persistent) were old…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyMyocardial InfarctionCritical Care and Intensive Care MedicineCoronary artery diseaseElectrocardiographyRecurrenceInternal medicinemedicineHumansProspective Studiescardiovascular diseasesMyocardial infarctionProspective cohort studyAgedHeart FailureUnivariate analysisEjection fractionProportional hazards modelbusiness.industryArrhythmias CardiacMiddle AgedPrognosismedicine.diseaseSurvival AnalysisLogistic ModelsHeart failureCardiologyFemaleCardiology and Cardiovascular MedicinebusinessMaceHeart & Lung
researchProduct

Diagnosis of perioperative myocardial necrosis following coronary artery surgery — a reappraisal of isoenzyme analysis

1990

Although the routine determination of CK-MB activity is widely used after coronary artery bypass grafting (CABG), the diagnosis of a perioperative myocardial necrosis remains arbitrary. The intention of the present study was to develop discriminative enzymatic parameters of CK-MB activity in a collective of 710 patients following CABG. Patients were grouped according to their postoperative electrocardiogram (ECG). For each patient, the time activity curve of CK-MB was determined. The total amount of CK-MB was calculated by integrating the area beneath the CK-MB activity curve. Patients presenting with an unchanged postoperative ECG (group I) or a new bundle branch block with uncompromised h…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyPercentileCardiac outputMyocardial InfarctionHemodynamicsElectrocardiographyInternal medicinemedicineHumansDerivationCoronary Artery BypassIntraoperative ComplicationsCreatine KinaseBundle branch blockbiologybusiness.industryHemodynamicsStroke VolumeGeneral MedicinePerioperativeMiddle AgedPrognosismedicine.diseaseIsoenzymesmedicine.anatomical_structureAnesthesiaCardiologybiology.proteinFemaleSurgeryCreatine kinaseCardiology and Cardiovascular MedicinebusinessArteryEuropean Journal of Cardio-Thoracic Surgery
researchProduct

Impact of moderate ischemic mitral regurgitation after isolated coronary artery bypass grafting

2009

The aim of the study was to evaluate the clinical and echocardiographic outcomes, at rest and under exercise testing, of patients with moderate ischemic mitral regurgitation (IMR) undergoing isolated coronary artery bypass graft surgery (CABG).Between February 2003 and March 2008, 180 patients with moderate IMR who had isolated CABG were enrolled. Patients were matched 1:2 (n = 360) with patients who underwent isolated CABG without IMR (by propensity score). The study endpoints were freedom from all death, cardiac related-death, late events, and cardiac-related events. Late outcomes and left ventricular remodeling were evaluated according to preoperative percent of ejection fraction. Sympto…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtycoronary artery byoass graftingRestmedicine.medical_treatmentMyocardial Ischemiamoderate ischemic mitral regurgitationCoronary Artery DiseaseCoronary artery diseaseInternal medicineMitral valvemedicineHumansMyocardial infarctionCoronary Artery BypassPropensity ScoreVentricular remodelingAgedMitral valve repairMitral regurgitationEjection fractionVentricular Remodelingbusiness.industryMitral Valve InsufficiencyMiddle Agedmedicine.diseaseSurgeryTreatment Outcomemedicine.anatomical_structureEchocardiographyExercise TestCardiologyFemaleSurgeryCardiology and Cardiovascular MedicinebusinessArtery
researchProduct

Multicentric study on the beta-blocker use and relation with exacerbations in COPD

2014

SummaryChronic obstructive pulmonary disease (COPD) is frequently associated with chronic heart failure (CHF) or coronary artery disease (CAD). In spite of the recommendation to use beta-blockers (BB) they are likely under-prescribed to patients with concurrent COPD and heart diseases. To find out the prevalence of use of BB, 256 COPD patients were consecutively recruited by pulmonary physicians from 14 hospitals in 7 regions of Spain in their outpatient offices if they had a diagnosis of COPD, were not on long-term oxygen therapy, had CHF or CAD, and met the criteria for BB treatment.In patients with indication 58% (95%CI, 52–64%) of the COPD patients and 97% of the non-COPD patients were …

MalePulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentPopulationAdrenergic beta-AntagonistsComorbidityCoronary Artery DiseaseEmergency treatmentSeverity of Illness IndexCoronary artery diseasePulmonary Disease Chronic ObstructiveRisk FactorsInternal medicineDiabetes mellitusOxygen therapymedicineHumansMyocardial infarctioneducationBeta blockerAgedAged 80 and overHeart Failureeducation.field_of_studyCOPDbusiness.industryAdverse effectsChronic obstructive pulmonary diseaseMiddle Agedmedicine.diseaseDrug UtilizationBronchodilator AgentsMyocardial infarctionCross-Sectional StudiesSpainHeart failureCardiologyFemalebusinessEmergency Service HospitalRespiratory Medicine
researchProduct

Arterial Stiffness is Related to Impaired Exercise Capacity in Patients With Coronary Artery Disease and History of Myocardial Infarction

2018

Background Augmented arterial stiffness and reduced cardiorespiratory fitness are associated with increased morbidity and mortality from coronary artery disease (CAD). The relationship between exercise capacity and arterial stiffness is independent of known influencing variables in CAD. This study aimed to analyse the interaction between exercise capacity, arterial stiffness and early vascular ageing in patients with CAD. Methods This cross-sectional study included 96 CAD patients with myocardial infarction (55.9 ± 10.9 years, 81 men) referred to cardiac rehabilitation. Arterial stiffness was assessed using carotid-femoral pulse wave velocity (cf-PWV). Cardiopulmonary exercise test was perf…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.medical_treatmentMyocardial InfarctionCoronary Artery DiseasePulse Wave Analysis030204 cardiovascular system & hematologyCoronary artery diseaseElectrocardiography03 medical and health sciencesVascular Stiffness0302 clinical medicineRisk FactorsInternal medicinemedicineHumansIn patientcardiovascular diseases030212 general & internal medicineMyocardial infarctionPulse wave velocityRetrospective StudiesExercise ToleranceRehabilitationPortugalbusiness.industryCardiorespiratory fitnessMiddle AgedExercise capacitymedicine.diseaseSurvival RateCarotid ArteriesCross-Sectional StudiesExercise Testcardiovascular systemArterial stiffnessCardiologyFemaleMorbidityCardiology and Cardiovascular MedicinebusinessFollow-Up StudiesHeart, Lung and Circulation
researchProduct

Vorapaxar in the secondary prevention of atherothrombotic events

2012

BACKGROUND: Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1. METHODS: We randomly assigned 26,449 patients who had a history of myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) or matching placebo and followed them for a median of 30 months. The primary efficacy end point was the composite of death from cardiovascular causes, myocardial infarction, or stroke. After 2 years, the data and safety monitoring board recommended discontinuation of the study treatment in patients …

MalePyridines[SDV]Life Sciences [q-bio]Myocardial InfarctionMedizinKaplan-Meier Estimate030204 cardiovascular system & hematologyBrain IschemiaLactones0302 clinical medicineMESH: Peripheral Arterial DiseaseSecondary PreventionMESH: Double-Blind Method030212 general & internal medicineMyocardial infarctionStrokeVorapaxarMESH: AgedAspirinMESH: Middle AgedMESH: RiskCardiovascular diseases [NCEBP 14]MESH: Secondary PreventionHazard ratioMESH: Brain IschemiaGeneral MedicineMiddle AgedClopidogrel3. Good healthStrokeMESH: Receptor PAR-1MESH: Myocardial Infarctionvorapaxar secondary prevention atherothrombotic eventsCardiovascular DiseasesMESH: Platelet Aggregation InhibitorsAnesthesiaRetreatmentPlatelet aggregation inhibitorFemaleIntracranial HemorrhagesMESH: HemorrhageMESH: Intracranial HemorrhagesMESH: Lactonescirculatory and respiratory physiologymedicine.drugRiskISQUEMIA CEREBRALHemorrhagePlaceboMESH: StrokePeripheral Arterial Disease03 medical and health sciencesDouble-Blind Method[INFO.INFO-IM]Computer Science [cs]/Medical ImagingmedicineHumansReceptor PAR-1MESH: RetreatmentMESH: Kaplan-Meier EstimateAgedMESH: Humansbusiness.industryMESH: PyridinesMESH: Cardiovascular Diseasesmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareMESH: MalebusinessMESH: FemalePlatelet Aggregation Inhibitors
researchProduct

Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): ra…

2004

Summary Background Clopidogrel was superior to aspirin in patients with previous manifestations of atherothrombotic disease in the CAPRIE study and its benefit was amplified in some high-risk subgroups of patients. We aimed to assess whether addition of aspirin to clopidogrel could have a greater benefit than clopidogrel alone in prevention of vascular events with potentially higher bleeding risk. Methods We did a randomised, double-blind, placebo-controlled trial to compare aspirin (75 mg/day) with placebo in 7599 high-risk patients with recent ischaemic stroke or transient ischaemic attack and at least one additional vascular risk factor who were already receiving clopidogrel 75 mg/day. D…

MaleRelative risk reductionTiclopidineHemorrhage030204 cardiovascular system & hematologyKlinikai orvostudományok03 medical and health sciences0302 clinical medicineDouble-Blind MethodRecurrenceRisk FactorsmedicineClinical endpointHumanscardiovascular diseasesMyocardial infarctionRisk factorStrokeAgedAspirinAspirinbusiness.industryAbsolute risk reductionGeneral MedicineOrvostudományokmedicine.diseaseClopidogrelClopidogrel3. Good healthStrokeIschemic Attack TransientAnesthesiaDrug Therapy CombinationFemalebusinessIntracranial HemorrhagesPlatelet Aggregation Inhibitors030217 neurology & neurosurgerymedicine.drug
researchProduct

Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes …

2015

Clinical data on the early and midterm outcomes of bioresorbable vascular scaffolds (BVS) in routine clinical practice are limited. To fill this gap, we report on the early and midterm clinical outcomes of PCI with everolimus-eluting BVS from the large multicentre GHOST-EU registry.Between November 2011 and January 2014, 1,189 patients underwent percutaneous coronary intervention with one or more BVS (Absorb BVS; Abbott Vascular, Santa Clara, CA, USA) at 10 European centres. The primary outcome of interest was target lesion failure (TLF), defined as the combination of cardiac death, target vessel myocardial infarction, or clinically driven target lesion revascularisation (TLR). A total of 1…

MaleReoperationTarget lesionmedicine.medical_specialtymedicine.medical_treatmentMyocardial InfarctionAntineoplastic AgentsComorbidityCoronary Artery DiseaseAngina PectorisPercutaneous Coronary InterventionRisk FactorsInterquartile rangeInternal medicineAbsorbable ImplantsDiabetes MellitusmedicineHumansCumulative incidenceEverolimusMyocardial infarctionAcute Coronary SyndromeAgedProportional Hazards ModelsTissue Scaffoldsbusiness.industryHazard ratioPercutaneous coronary interventionDrug-Eluting StentsThrombosisMiddle Agedmedicine.diseaseThrombosisSurgeryEuropeTreatment OutcomeCardiovascular DiseasesConventional PCICardiologyFemaleCardiology and Cardiovascular MedicinebusinessEuroIntervention
researchProduct

Procedural, Functional and Prognostic Outcomes Following Recanalization of Coronary Chronic Total Occlusions. Results of the Iberian Registry.

2019

Introduction and objectives: There is current controversy regarding the benefits of percutaneous recanalization (PCI) of chronic total coronary occlusions (CTO). Our aim was to determine acute and follow-up outcomes in our setting. Methods: Two-year prospective registry of consecutive patients undergoing PCI of CTO in 24 centers. Results: A total of 1000 PCIs of CTO were performed in 952 patients. Most were symptomatic (81.5%), with chronic ischemic heart disease (59.2%). Previous recanalization attempts had been made in 15%. The mean SYNTAX score was 19.5 +/- 10.6 and J-score was > 2 in 17.3%. A retrograde procedure was performed in 92 patients (9.2%). The success rate was 74.9% and was hi…

MaleReoperationmedicine.medical_specialtyPercutaneousmedicine.medical_treatmentPerforation (oil well)Myocardial Ischemia030204 cardiovascular system & hematology03 medical and health sciencesPercutaneous Coronary InterventionPostoperative Complications0302 clinical medicineInternal medicineMyocardial RevascularizationmedicineHumansProspective StudiesRegistriesMyocardial infarctionProspective cohort studyUltrasonography InterventionalAgedPortugalbusiness.industryMortality ratePercutaneous coronary interventionGeneral Medicinemedicine.diseaseTreatment OutcomeCoronary OcclusionSurgery Computer-AssistedSpainCoronary occlusionChronic DiseaseConventional PCICardiologyFemaleCTO Cardiopatía isquémica crónica Chronic ischemic cardiomyopathy Chronic total occlusions IVUS OCT Oclusiones crónicasbusiness
researchProduct